BenzingaOctober 20, 2026 at 8:51 AM NY7 Days Ago
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
